Cingulate Therapeutics

Cingulate Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, precision-timed therapeutics for central nervous system (CNS) disorders. Its core innovation is the Precision Timed Release™ (PTR™) platform, which enables the creation of single-dose, multi-pulse formulations designed to enhance efficacy and adherence. The company's strategy is to advance its late-stage pipeline in ADHD and anxiety, aiming to address significant unmet needs in large, established markets where current treatments suffer from pharmacokinetic limitations. Having gone public in 2021, Cingulate is now focused on executing its pivotal clinical trials to generate value-driving data.

Proprietary Precision Timed Release™ (PTR™) drug delivery platform, an engineered multi-particulate system designed to provide precise, timed multi-pulse drug release from a single oral dose to maintain therapeutic drug levels.

Cingulate competes in crowded ADHD and anxiety markets dominated by generics and established branded products. Differentiation hinges on proving its PTR™ formulations offer clinically superior duration, consistency, or tolerability. It also faces potential competition from other drug delivery platforms.